These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 2116945)
1. Hormonal changes in patients with polycystic ovarian disease after ovarian electrocautery or pituitary desensitization. Gadir AA; Khatim MS; Mowafi RS; Alnaser HM; Alzaid HG; Shaw RW Clin Endocrinol (Oxf); 1990 Jun; 32(6):749-54. PubMed ID: 2116945 [TBL] [Abstract][Full Text] [Related]
2. Hormonal response to electrocautery of the ovary in patients with polycystic ovarian disease. Aakvaag A; Gjønnaess H Br J Obstet Gynaecol; 1985 Dec; 92(12):1258-64. PubMed ID: 3936533 [TBL] [Abstract][Full Text] [Related]
3. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease. de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501 [TBL] [Abstract][Full Text] [Related]
4. Pituitary and ovarian responses to LHRH stimulation in women with clinical features of the polycystic ovary syndrome. Heineman MJ; Thomas CM; Doesburg WH; Rolland R Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):273-84. PubMed ID: 6430731 [TBL] [Abstract][Full Text] [Related]
5. Endocrine effects of ovarian electrocautery in patients with polycystic ovarian disease. Gjønnaess H; Norman N Br J Obstet Gynaecol; 1987 Aug; 94(8):779-83. PubMed ID: 3117092 [TBL] [Abstract][Full Text] [Related]
6. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns. Kuhl H; Jung C; Taubert HD Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376 [TBL] [Abstract][Full Text] [Related]
7. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome. Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757 [TBL] [Abstract][Full Text] [Related]
10. Effect of ovarian wedge resection for the Stein-Leventhal syndrome on plasma FSH, LH, oestradiol and testosterone levels and on the responses of the pituitary to intravenous LHRH. Valkov IM; Dokumov SI Br J Obstet Gynaecol; 1977 Jul; 84(7):539-42. PubMed ID: 334239 [TBL] [Abstract][Full Text] [Related]
11. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986 [TBL] [Abstract][Full Text] [Related]
12. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme. Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103 [TBL] [Abstract][Full Text] [Related]
13. GnRH-agonist therapy in women with the polycystic ovarian syndrome: effects on ovarian volume and on gonadotropin and sex steroid levels. Dale PO; Tanbo T; Haug E; Abyholm T Gynecol Endocrinol; 1989 Dec; 3(4):309-15. PubMed ID: 2516706 [TBL] [Abstract][Full Text] [Related]
14. The prognostic value of basal luteinizing hormone:follicle-stimulating hormone ratio in the treatment of patients with polycystic ovarian syndrome by assisted reproduction techniques. Tarlatzis BC; Grimbizis G; Pournaropoulos F; Bontis J; Lagos S; Spanos E; Mantalenakis S Hum Reprod; 1995 Oct; 10(10):2545-9. PubMed ID: 8567767 [TBL] [Abstract][Full Text] [Related]
15. Classification of secondary amenorrhea based on distinct hormonal patterns. Kletzky OA; Davajan V; Nakamura RM; Mishell DR J Clin Endocrinol Metab; 1975 Oct; 41(4):660-8. PubMed ID: 1176579 [TBL] [Abstract][Full Text] [Related]
16. Effect of long-term inhibition of gonadotrophin secretion by the gonadotrophin-releasing hormone agonist, buserelin, on sex steroid secretion and ovarian morphology in polycystic ovary syndrome. Macleod AF; Wheeler MJ; Gordon P; Lowy C; Sönksen PH; Conaglen JV J Endocrinol; 1990 May; 125(2):317-25. PubMed ID: 2115566 [TBL] [Abstract][Full Text] [Related]
17. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Faure N; Lemay A Clin Endocrinol (Oxf); 1987 Dec; 27(6):703-13. PubMed ID: 3138052 [TBL] [Abstract][Full Text] [Related]
18. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma. Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963 [TBL] [Abstract][Full Text] [Related]
19. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome. Judd HL; Rigg LA; Anderson DC; Yen SS J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366 [TBL] [Abstract][Full Text] [Related]
20. Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian disease. Mongioi A; Maugeri G; Macchi M; Calogero A; Vicari E; Coniglione F; Aliffi A; Sipione C; D'Agata R Acta Endocrinol (Copenh); 1986 Feb; 111(2):228-34. PubMed ID: 3082098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]